TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02881320
Drug: B/F/TAF (TOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x B/F/TAF 1.88/7.5/0.94 mg (total daily dose 3.76/15/1.88 mg) FDC tablets administered orally as TOS, twice daily
Study: NCT01874366
Drug: P11187
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Part I: Step wise dose escalation(10 to 1500 mg, qd, Oral)~* Part II: Step wise dose escalation in multiple dosing (≤ 1500 mg, qd, Oral) for 14 consecutive days.~* Part III: Study drug administered (≤ 1500 mg, qd, Oral) under fasted or fed conditions in two different periods separated by a wash-out interval.
Study: NCT01515865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of matching placebo
Study: NCT01874366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will be matching in appearance with the active drug capsules of P11187.~* In Part I, there will be up to 6 cohorts of 8 subjects each in single dose assessment. Two subjects from each cohort will be dosed with placebo~* In Part II, there will be 3 cohorts of 12 subjects each and three subjects from each cohort will be dosed with placebo
Study: NCT00191542
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00641537
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
Study: NCT00641537
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
Study: NCT03999164
Drug: [18F]DPA-714 Positron Emission Tomography Scan
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will undergo a \[18F\]DPA-714 PET scan of the brain 2 weeks and 2 months following moderate to severe traumatic brain injury to quantify neuroinflammation.
Study: NCT00419848
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cap 100mg- 100mg/daily
Study: NCT03592667
Drug: Placebo - Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: One per day before breakfast during 12 weeks.
Study: NCT00489333
Drug: ProAlgaZyme
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03994302
Drug: Drug inducing antiphospholipid syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs susceptible to induce immune toxicities such as antiphospholipid syndrome
Study: NCT00876538
Drug: Placebo Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Control 2 capsules once day with the noon meal
Study: NCT01895270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will consist of microcrystalline cellulose.
Study: NCT03391570
Drug: COX-2 inhibitor
Normalized name: COX-2 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celebrex 200mg/1cap 2 tablets, take medication an hour before surgery
Study: NCT03391570
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramnos 250mg/1cap 2 tablets, take medication an hour before surgery
Study: NCT00869856
Drug: HX575 solution for s.c. administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Containing different strengths of epoetin alfa (1 to 10 KIU), s.c. injection, 1x per week (qw) or 1x every two weeks (q2w), injection into abdomen or upper thigh
Study: NCT00297128
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
Study: NCT00954057
Drug: LIPO-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: intraorbital injection
Study: NCT00954057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intraorbital injection
Study: NCT00756236
Drug: P-Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9%NaCl dispensed in 60ml \& 5ml syringes
Study: NCT04565717
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9% NaCl) matching volume of ALN-HSD doses will be administered SC.
Study: NCT00127998
Drug: artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03386643
Drug: Bifidobacterium animalis subsp. lactis HN019
Approvals — FDA: no, EMA: no, PMDA: no
Description: The selected patients will receive capsules to be diluted in 15 ml of water containing 6 x 109 CFUs of Bifidobacterium subsp. lactis HN019 for mouthwash twice a day for 4 weeks.
Study: NCT04427475
Drug: pabolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 patients with stage IV EGFR / ALK wild-type NSCLC (squamous cell carcinoma patients do not need to be detected) who received anti-PD-1 (pabolizumab) treatment combined with chemotherapy as the first-line treatment were enrolled in the center. Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles. At the same time, plasma samples were collected at key nodes until the patient's progress.
Study: NCT04270409
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AxMP/pre-medication ATC code: N02BE01 Pharmaceutical form: tablet/ampule/capsule; Route of administration: Intravenous (IV) or per os (PO)
Study: NCT04270409
Drug: Methylprednisolone or equivalent
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AxMP/pre-medication; ATC code: H02AB04; Pharmaceutical form: vial; Route of administration: Intravenous
Study: NCT02073448
Drug: CD0271
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02073448
Drug: CD1579
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00552253
Drug: Levothyroxin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxin 100 micogram will be administered once daily 1 hour before meal of just after meal for 3 months, and the dose will be titrate to keep serum TSH level between 0.1\~0.3 mU/L. It will be discontinued for 3 months. Then
Study: NCT03499899
Drug: LAG525
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAG525 was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 400mg every 21 days. For all arms, LAG525 was infused first
Study: NCT03499899
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spartalizumab was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 300mg every 21 days. Spartalizumab was infused after LAG525
Study: NCT03697603
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, once daily, 14 weeks
Study: NCT01404754
Drug: Lactose (inactive placebo)
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in an equivalent weight to midomafetamine HCl will be administered in identical appearing capsules during one of two experimental sessions. An equivalent to the initial and supplemental dose will exist.
Study: NCT00527033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03593785
Drug: AZD8233
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized subjects will receive single SC dose of AZD8233 (dose 1, dose 2, dose 3, dose 4 and dose 5) injection.
Study: NCT04493359
Drug: Renin-angiotensin system inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: switch anti-hypertensive class
Study: NCT00293410
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01489254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily) for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
Study: NCT02958566
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03063086
Drug: QVM149 150/50/160 μg o.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: B
Study: NCT01893281
Drug: Topical Testosterone Solution
Normalized name: testosterone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered topically to axillae.
Study: NCT02958566
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02958566
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02958566
Drug: Hydrocodone-Acetaminophen Tab 5-325 MG
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02958566
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PCA
Study: NCT00507819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo capsule will be taken by mouth three times-a-day.
Study: NCT02218736
Drug: CERC-501
Normalized name: CERCIS SILIQUASTRUM WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosing of 10 mg CERC-501 daily for 8 weeks
Study: NCT02958566
Drug: HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
Normalized name: hydrocodone/acetaminophen 5 mg-325 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakthrough
Study: NCT02218736
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dosing of 10 mg placebo daily for 8 weeks
Study: NCT00965978
Drug: ONO-5920 / YM529
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00767728
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules (4 capsules) were administered orally QD, in the morning.
Study: NCT02972424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo as a prefilled syringe with all inactive ingredients
Study: NCT00829140
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02387957
Drug: Fovista®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02877511
Drug: BAY987517
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied liberally to the skin (Formulation: Y73-161
Study: NCT01111123
Drug: Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid on weekends only group
Study: NCT01111123
Drug: Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo on weekends only group
Study: NCT03107884
Drug: Placebo (Bed Rest)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin treatment group
Study: NCT03107884
Drug: Placebo (2 week run-in only)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin 2 week run-in treatment group.
Study: NCT06613633
Drug: third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with advanced EGFR-mutated NSCLC who met the inclusion criteria and received third-generation EGFR-TKI (monotherapy or combined with brain radiotherapy)
Study: NCT00900159
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo prior to daytime sleep for 3 days (at home) and 1 day (in lab)
Study: NCT02438826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04437420
Drug: injection of BEP 800
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of BEP 800
Study: NCT03831464
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention will consist in IMP treatment during 30 months with half of the patients treated with matched placebo. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.
Study: NCT03502070
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose (4 capsules) of placebo
Study: NCT04419532
Drug: DS-1055a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an intravenous infusion on Day 1 of every 21-day cycle following low dose administration(s) in priming dose period.~Infusion duration: 180 minutes for the first infusion, and if no infusion-related reaction, 120 minutes for subsequent infusions
Study: NCT01865708
Drug: Ethanol Lock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol lock, utilizing 74% ethanol, will begin within 24 hours of urinary catheter placement. The lock will be done every 24 hours for 1 hour. The volume that will be instilled depends upon the fill volume of the catheter, which is imprinted by the manufacturer on each catheter. Once the alcohol is in the catheter, the proximal end of the catheter will be clamped for 1 hour. After the 1 hour dwell time, the clamp will be removed and the alcohol in the lumen of the catheter will be flushed out by the patient's own urine output.
Study: NCT01735201
Drug: AGN-199201 Dose A
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-199201 Dose A applied once or twice daily to the face for 28 days.
Study: NCT00297180
Drug: GW869682
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01735201
Drug: AGN-199201 Vehicle
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-199201 Vehicle applied once or twice daily to the face for 28 days.
Study: NCT04333420
Drug: Placebo + SOC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase III study part: Placebo + SOC
Study: NCT00752843
Drug: mifepristone + fluvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single oral dose of 40 mg PO of fluvastatin on three occasions: alone (Day 1), at the same time as a single dose of CORLUX 1200 mg (Day 8) and during concomitant administration of CORLUX 1200 mg/day (CORLUX on Days 8-14, fluvastatin on Day 14).
Study: NCT01455532
Drug: Pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous
Study: NCT03686228
Drug: No-PB-MNC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive ASA 81 mg once daily and wound care and pain killer drug
Study: NCT01497912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once daily for 8 weeks
Study: NCT02737943
Drug: Zagazig
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care is an antibiotic ointment in combination of analgesic for relief of pain.
Study: NCT03636971
Drug: hyaluronic acid with sorbitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: single shot injection (Synolis®, Gebro-Pharma AG, CH, 2000 kD)
Study: NCT01045577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching masitinib (3 mg/kg/day and 6 mg/kg/day)
Study: NCT02953847
Drug: Rimactazid 150/75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin/isoniazid 150/75 mg This 2-drug FDC is one of 2 widely used 2-drug FDCs in South Africa, with an estimated 30% of the SA DOH tender. Rifinah® made by Sanofi-Aventis holds about 70% of the tender, however as the Sanofi-Aventis 4-drug FDC will also be evaluated.
Study: NCT03448731
Drug: Doxycycline 50Mg Tablet
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline administered p.o once daily at a 50 mg dose for 6 weeks beginning on Day -1
Study: NCT02449382
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the serum sodium concentration ≤150mmol/L, When filter occurred clotting, as the end of treatment.
Study: NCT00107965
Drug: PEP005
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0025% PEP005 Topical Gel (Day 1,2 application)
Study: NCT00107965
Drug: PEP005
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% PEP005 Topical Gel (Day 1,2 application)
Study: NCT03391609
Drug: placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caesarian section will be performed under standard general anesthesia plus pre and intra operative saline infusion (placebo) in the same rate as dexmedetomedine starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
Study: NCT03887026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule
Study: NCT03183089
Drug: Rohto Dry-Aid®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04610567
Drug: Methotrexate-LDE phase 1
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 patients will receive MTX-LDE at the dose of 15mg IV each 7 days during hospitalization, up to 3 times . After that, 9 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times .~All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE
Study: NCT04610567
Drug: Methotrexate-LDE phase 2
Normalized name: methotrexate 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE
Study: NCT04610567
Drug: Placebo-LDE phase 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44 patients will receive Placebo-LDE IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of Placebo-LDE
Study: NCT00005944
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005944
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005944
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00892502
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
Study: NCT05736640
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02660281
Drug: Pre-Stem Cell Infusion Cyclophosphamide
Normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide given prior to the stem cell infusion
Study: NCT02660281
Drug: Post-Stem Cell Infusion Cyclophosphamide
Normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide given after the stem cell infusion
Study: NCT01656811
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2 actuations QID
Study: NCT00836381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical Placebo once daily
Study: NCT01794182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT03131973
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT03131973
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT03131973
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT03131973
Drug: Flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04448457
Drug: Sufentanil Sublingual Tablet
Normalized name: SUFentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mcg with lockout interval of 20 min
Study: NCT01987739
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04523272
Drug: TQB2450
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study: NCT01167114
Drug: STA-9090
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intravenously on Day 1, 8 and 15 of each 4 week cycle.
Study: NCT03371017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered, 1200 mg by IV infusion with :~gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle
Study: NCT03371017
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle
Study: NCT03098654
Drug: DM/HTN medications as needed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive DM or HTN medications prescribed by the CTC clinician as needed.
Study: NCT02173678
Drug: COMBIVENT® CFC-MDI
Approvals — FDA: no, EMA: no, PMDA: no